Overview
- Hims & Hers disclosed preliminary discussions to offer Wegovy injections and a future oral version on its platform, and Novo confirmed the talks.
- Management warned there is a possibility no definitive agreement will be executed with Novo Nordisk.
- Third-quarter revenue reached about $599–$600 million, topping estimates, while adjusted earnings of $0.06 per share missed forecasts.
- Hims guided fourth-quarter revenue to $605–$625 million, below consensus, and narrowed its full-year outlook to roughly $2.335–$2.355 billion.
- Subscribers grew about 21% to roughly 2.47–2.5 million and shares rose about 5%–6% after the update, as investors weighed renewed Novo talks and lingering regulatory overhang from earlier GLP‑1 disputes.